Tag
Anupam Rasayan India Limited
7 articles
Anupam Rasayan is undergoing significant strategic shifts as it solidifies its position in the specialty chemicals sector. The company recently launched a mandatory open offer to acquire a 26% stake in Bliss GVS Pharma, following a Share Purchase Agreement to obtain a 43.3% controlling interest, signaling a move towards expanding its pharmaceutical ingredient offerings. Simultaneously, Anupam Rasayan appointed Ravi Desai as Chief Operating Officer, leveraging his extensive experience to drive operational efficiency and sales growth, while also reporting a net profit of ₹386.39 million for Q1 FY27. These developments suggest Anupam Rasayan is actively pursuing growth through acquisitions and internal leadership enhancements, potentially reshaping its competitive landscape and creating opportunities for investors.
Anupam Rasayan Q1 FY27 Earnings Call Recording Available
Anupam Rasayan India Limited informed exchanges that audio recording of its Q1 FY27 earnings call is now available on company website.
The earnings call discussed unaudited standalone and consolidated
Anupam Rasayan Q1 Revenue Up 36% YoY
Anupam Rasayan reported unaudited Q1FY27 consolidated revenue of ₹6,675 Mn, up 36% YoY, with EBITDA of ₹1,749 Mn.
The company signed a Letter of Intent with BASQUEVOLT for a potential $300 million sup
Anupam Rasayan Appoints Ravi Desai as Chief Operating Officer
Anupam Rasayan India Ltd's Board appointed Mr. Ravi Desai as Chief Operating Officer, effective August 14, 2026.
Mr. Desai, with over 20 years in specialty chemicals, was previously the Company's Sale
Anupam Rasayan Q1 FY27 Net Profit at ₹386.39M
Board approved unaudited standalone and consolidated financial results for Q1 FY27 ending June 30, 2026.
Appointed Mr. Ravi Desai as Chief Operating Officer, effective August 14, 2026, while continuin
Anupam Rasayan Allots 1,531 ESOP Shares
Anupam Rasayan India Limited's NRC approved the allotment of 1,531 equity shares at ₹225 per share under its ESOP 2020 plan.
The allotment increases the company's paid-up capital to ₹113.85 crore from
Bliss GVS Open Offer Addendum Adds Mates Visa as PAC
Bliss GVS Pharma received an addendum to an open offer from Anupam Rasayan, designating Mates Visa Consultancy as a person acting in concert (PAC).
The addendum, dated July 17, 2026, discloses Mates V
Anupam Rasayan Open Offer for 26% Bliss GVS
Anupam Rasayan India Limited launched a mandatory open offer for 26% of Bliss GVS Pharma's expanded voting capital at ₹299 per share.
The offer, triggered by a Share Purchase Agreement to acquire a 43